PCM
HRMY icon

Penn Capital Management’s Harmony Biosciences HRMY Stock Holding History

Penn Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-197,554
Closed -$6.48M – 154
2023
Q1 		$6.48M Buy
197,554
+21,567
+12% +$982K 0.65% 67
2022
Q4 		$9.71M Buy
175,987
+43,362
+33% +$2.38M 0.99% 49
2022
Q3 		$5.88M Buy
+132,625
New +$6.47M 0.66% 67

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Penn Capital Management's HRMY Position: Q2 2023 in Review

Penn Capital Management sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 197,554 shares — an estimated $6.48M sold.

Penn Capital Management first reported a position in HRMY in Q3 2022 and held it in 3 quarters. The position peaked at $9.71M in Q4 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Penn Capital Management reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Penn Capital Management sold 197,554 Harmony Biosciences shares in Q2 2023, an estimated $6.48M.
  • Penn Capital Management first reported a position in Harmony Biosciences in Q3 2022 and held it in 3 quarters.
  • Penn Capital Management's Harmony Biosciences position peaked at $9.71M in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Penn Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.